tetano
Editor, Senior Moderator
Vaccine. 2017 Jan 19. pii: S0264-410X(17)30046-4. doi: 10.1016/j.vaccine.2017.01.025. [Epub ahead of print]
[h=1]Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.[/h] Moriyama M[SUP]1[/SUP], Chino S[SUP]1[/SUP], Ichinohe T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Mucosal immunity induced through natural infection by influenza virus has potent cross-protective activity, compared to subcutaneous vaccination-induced systemic immunity. Compared to natural infection with influenza virus, however, a single intranasal vaccination with an inactivated influenza virus vaccine and poly(I:C) is not sufficient to induce primary immune response in na?ve animals. The reasons for this moderate effect are not fully understood. Here, we demonstrated that intranasal vaccination with formalin-inactivated influenza virus vaccine and poly(I:C) for five consecutive days elicits high levels of virus-specific nasal IgA and serum IgG responses, while vaccination without poly(I:C) induced little response. Mice immunized with influenza virus vaccine and poly(I:C) for five consecutive days sustained high levels of virus-specific IgA in nasal wash and IgG in serum until at least 6months after vaccination. Furthermore, intranasal vaccination with influenza virus vaccine and poly(I:C) protected mice against homologous and heterologous influenza virus challenge. These results suggest that consecutive inoculations of influenza virus vaccine and poly(I:C) is an alternative method to induce primary immune responses in na?ve subjects.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Adjuvant; IgA; Influenza virus; Intranasal vaccine; poly(I:C)
PMID: 28111142 DOI: 10.1016/j.vaccine.2017.01.025
[PubMed - as supplied by publisher]
[h=1]Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.[/h] Moriyama M[SUP]1[/SUP], Chino S[SUP]1[/SUP], Ichinohe T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Mucosal immunity induced through natural infection by influenza virus has potent cross-protective activity, compared to subcutaneous vaccination-induced systemic immunity. Compared to natural infection with influenza virus, however, a single intranasal vaccination with an inactivated influenza virus vaccine and poly(I:C) is not sufficient to induce primary immune response in na?ve animals. The reasons for this moderate effect are not fully understood. Here, we demonstrated that intranasal vaccination with formalin-inactivated influenza virus vaccine and poly(I:C) for five consecutive days elicits high levels of virus-specific nasal IgA and serum IgG responses, while vaccination without poly(I:C) induced little response. Mice immunized with influenza virus vaccine and poly(I:C) for five consecutive days sustained high levels of virus-specific IgA in nasal wash and IgG in serum until at least 6months after vaccination. Furthermore, intranasal vaccination with influenza virus vaccine and poly(I:C) protected mice against homologous and heterologous influenza virus challenge. These results suggest that consecutive inoculations of influenza virus vaccine and poly(I:C) is an alternative method to induce primary immune responses in na?ve subjects.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Adjuvant; IgA; Influenza virus; Intranasal vaccine; poly(I:C)
PMID: 28111142 DOI: 10.1016/j.vaccine.2017.01.025
[PubMed - as supplied by publisher]